The biotech industry in 2024: A retrospective look
This issue of our newsletter is supported by Inpart.
As 2024 comes to a close, it’s time to take a look back at what happened in biotech this year. Did the industry witness a triumphant 2024 or another year of cautious optimism? Well, perhaps it was a little bit of both.
CRISPR built on its 2023 momentum, there were some notable drug approvals in different areas, and it was a year of megadeals. However, the total number of deals declined compared to previous years and pharmaceutical M&A activity hit a low in 2024, marking the lowest level of dealmaking in nearly a decade.
So, while the year has overall been relatively positive, biotech is still far from its record performance during the pandemic and has continued to face certain challenges.
To find out more, read the full article: “Biotech in 2024: A retrospective”
A MESSAGE FROM OUR SPONSOR INPART
Antibody Therapy: R&D trends and breakthrough innovations
Interested in high-impact science driving antibody therapy R&D?
Download Inpart’s latest report and take stock of the R&D landscape, the most sought-after early-stage breakthroughs, and the most active institutes and biotechs.
Want to advertise with us? Become our next sponsor.
🔥 More noteworthy articles from this week:
Idiopathic pulmonary fibrosis is a rare condition where the lungs become scarred, making it hard to breathe. The cause of the disease is unknown, which is why it is called ‘idiopathic.’ So far, U.S. regulators have only approved two drugs for the treatment of idiopathic pulmonary fibrosis and patients have unmet needs. There is a lot of research going on in the field at present, in the hope that more therapies reach patients sooner.
As big pharma faces a looming patent cliff that could put more than $200 billion in annual revenue at risk through 2030, it opens up a major opportunity for biosimilar developers. This is because, unlike the patent cliff at the start of the last decade, which primarily involved chemical pills that previously dominated the market for big pharma, this one includes a fair number of biologics, making the transition to biosimilars highly significant. In this article, we take a look at five biosimilar companies hoping to capitalize on this situation.
The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024. Around the world, oncology, central nervous system (CNS), and genetic disorder players attracted the biggest funding rounds overall.
When German scientists posted data in 2022 showing that CAR-T cell therapy could be effective in treating systemic lupus erythematosus, interest in the field quickly took off. More recently, spurring interest even further, the researchers posted an update in February 2024, showing results from a case series in which 15 autoimmune disease patients, eight of which had systemic lupus erythematosus, all achieved complete remission after receiving a single infusion of CAR-T therapy.
Our guest on this podcast episode is Adam Marťák, the founder and CEO of ambiom, a life science commercial-advisory business development company based in the Slovakian capital of Bratislava. We discuss the biotech scene in Eastern Europe, the company, and look at some of the challenges facing biotech companies as they navigate the financial pathway alongside drug discovery, regulations, and commercialization.
The market for 3D cell models is projected to skyrocket from $1.42 billion to $5.29 billion by 2032. This is fueled by their ability to offer a more accurate representation of human tissues than traditional 2D cultures, and they are already playing a pivotal role in advancing disease research and drug development across areas such as oncology, neuroscience, and immunology. Our Sartorius-sponsored report looks at the groundbreaking impact of 3D organoids, examining their evolution, advantages, current applications, and future potential.
The clinical development process is long, often exceeding 10 years from discovery through regulatory approval for a drug candidate. Whereas established companies have experience in all clinical trial phases, in-house regulatory expertise, and are equipped to run large, standardized trials, smaller biotechs have limited financing, fewer established processes, and may outsource parts of their drug development process to specialized vendors. In this article, we’ll explore challenges in clinical trial design and show how choosing the right software solution can drastically improve the probability of clinical trial success.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.